Cipla Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹7,404 Cr −2.4% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
C

Cipla Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Cipla Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹7,119Cr
+2.3% YoY
+8.8% QoQ
Net profit
₹786Cr
−39.2% YoY
+44.8% QoQ
Margin
17%
−9 pp YoY
+2 pp QoQ

What the Q1 FY27 call signalled

2 of 3 strong

RevenueModerate growth
MarginMargins slightly up
CapexCapex planned
Price₹1,325
Market cap₹1.1L Cr
P/E29.9

The short version

Cipla targets meaningful growth leading to a $1 billion exit in North America, driven by large new product launches expected to ramp up through the year. Cipla's current EBITDA margin (~16.7%) is below steady-state due to operating expenses from new product launches and temporary war impacts (1-2% margin hit). - The company expects sharp margin improvement as new products start generating revenue and facilities become better utilized. - Cost optimization and productivity initiatives are underway to support margin growth. - EBITDA margin guidance is 18.5% to 20% for FY27, predicated on successful new launches. - Cipla refrains from providing specific long-term margin targets but aims for gradual sequential margin improvement. - New product launches in the U.S.

From Cipla Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • Cipla targets meaningful growth leading to a $1 billion exit in North America, driven by large new product launches expected to ramp up through the year.
  • New product launches in the U.S. (including 3 respiratory assets and a key peptide opportunity) are expected to contribute significantly to revenue, with supply scaling towards the end of the financial year.
  • India business is focused on sustaining growth momentum with a double-digit growth trajectory, especially in chronic therapies like respiratory, diabetes, cardiology, urology, and dermatology. Chronic portfolio in India is targeted to increase from 60% now to possibly around 65% in 2-3 years.

2 more points from Cipla Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Cipla Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Cipla has increased capex focused on organic growth.
  • Significant investments are directed toward R&D, especially biosimilars.
  • The company is actively pursuing differentiated portfolios through acquisitions or in-licensing, which may require upfront payments.

2 more points from Cipla Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Cipla Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Related business outlook insights include: - Cipla is expecting growth driven by new product launches, especially in the U.S. with three respiratory products and one large peptide product awaiting approval and launch. - The U.S. business aims for a $1 billion exit revenue run rate in FY27, relying significantly on these new product launches. - India business expects stable manpower with focus on productivity rather than large additions, indicating steady order processing.

2 more points from Cipla Ltd's call on order book

Create a free account to keep reading this call

Cipla Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Cipla Ltd Q1 FY27 results — key figures

Cipla Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue7,1196,957+2.3%6,541+8.8%
Operating profit (EBITDA)1,1921,778-33%955+24.8%
Operating margin17%26%-9 pp15%+2 pp
Profit before tax1,0821,770-38.9%707+53%
Net profit (PAT)7861,292-39.2%543+44.8%
EPS (₹)9.7716.06-39.2%6.87+42.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹7.4K Cr, net profit ₹852 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cipla Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cipla Ltd Q1 FY27 results?

Cipla targets meaningful growth leading to a $1 billion exit in North America, driven by large new product launches expected to ramp up through the year. Cipla's current EBITDA margin (~16.7%) is below steady-state due to operating expenses from new product launches and temporary war impacts (1-2% margin hit). - The company expects sharp margin improvement as new products start generating revenue and facilities become better utilized. - Cost optimization and productivity initiatives are underway to support margin growth. - EBITDA margin guidance is 18.5% to 20% for FY27, predicated on successful new launches. - Cipla refrains from providing specific long-term margin targets but aims for gradual sequential margin improvement. - New product launches in the U.S.

What is Cipla Ltd share price analysis?

Cipla Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.9 with a market cap of ₹107,051 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cipla Ltd planning capital expenditure?

Cipla has increased capex focused on organic growth. - Significant investments are directed toward R&D, especially biosimilars. - The company is actively pursuing differentiated portfolios through acquisitions or in-licensing, which may require upfront payments. - They continue to explore M&A opportunities in the U.S.

Keep Cipla Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.